Prometheus Biosciences (NASDAQ:RXDX) Price Target Raised to $144.00
Prometheus Biosciences (NASDAQ:RXDX) Price Target Raised to $144.00
Prometheus Biosciences (NASDAQ:RXDX – Get Rating) had its price target raised by The Goldman Sachs Group from $117.00 to $144.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's price target would suggest a potential upside of 31.30% from the company's previous close.
據Benzinga報道，在週二發佈的一份報告中，高盛將普羅米修斯生物科學公司(納斯達克：RXDX-GET評級)的目標價從117.00美元上調至144.00美元。該公司目前對這家生物製藥公司的股票給予“買入”評級。高盛的目標股價表明，該公司較前一交易日收盤價有31.30%的潛在上行空間。
Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus lifted their target price on shares of Prometheus Biosciences from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 1st. Credit Suisse Group lifted their price target on shares of Prometheus Biosciences from $59.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, December 8th. Royal Bank of Canada boosted their target price on shares of Prometheus Biosciences from $66.00 to $111.00 in a report on Wednesday, December 7th. Piper Sandler upped their price target on shares of Prometheus Biosciences from $67.00 to $114.00 in a report on Wednesday, December 7th. Finally, BTIG Research upped their price target on shares of Prometheus Biosciences from $74.00 to $181.00 and gave the company a "buy" rating in a report on Thursday, December 8th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $117.10.
其他股票研究分析師最近也發佈了關於該股的研究報告。Stifel Nicolaus在11月1日(星期二)的一份研究報告中將普羅米修斯生物科學公司的股票目標價從50.00美元上調至55.00美元，並給予該股“買入”評級。瑞士信貸集團在12月8日週四的一份報告中將普羅米修斯生物科學公司的股票目標價從59美元上調至142.00美元，並給予該公司“跑贏大盤”的評級。在12月7日週三的一份報告中，加拿大皇家銀行將普羅米修斯生物科學公司的股票目標價從66美元上調至111.00美元。派珀·桑德勒在12月7日週三的一份報告中將普羅米修斯生物科學公司的股票目標價從67美元上調至114.00美元。最後，BTIG Research在12月8日星期四的一份報告中將普羅米修斯生物科學公司的股票目標價從74美元上調至181.00美元，並給予該公司“買入”評級。根據MarketBeat.com的數據，九位投資分析師對該股的評級為買入，該公司的共識評級為買入，共識目標價為117.10美元。
Prometheus Biosciences Stock Performance
普羅米修斯生物科學公司股票表現
NASDAQ RXDX opened at $109.67 on Tuesday. The company has a quick ratio of 11.19, a current ratio of 11.19 and a debt-to-equity ratio of 0.11. The company has a 50-day simple moving average of $98.90 and a two-hundred day simple moving average of $66.80. The firm has a market cap of $4.60 billion, a price-to-earnings ratio of -32.74 and a beta of -0.46. Prometheus Biosciences has a 12-month low of $21.50 and a 12-month high of $122.75.
納斯達克RXDX週二開盤報109.67美元。該公司的速動比率為11.19，流動比率為11.19，債務權益比為0.11。該公司的50日簡單移動均線切入位98.90美元，200日簡單移動均線切入位66.80美元。該公司的市值為46億美元，市盈率為-32.74倍，貝塔係數為-0.46。普羅米修斯生物科學公司的12個月低點為21.5美元，12個月高位為122.75美元。
Insider Activity at Prometheus Biosciences
普羅米修斯生物科學公司的內部活動
In other news, CEO Mark C. Mckenna sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $118.99, for a total transaction of $2,974,750.00. Following the completion of the sale, the chief executive officer now owns 55,144 shares in the company, valued at approximately $6,561,584.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Keith W. Marshall sold 5,000 shares of the company's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $119.00, for a total transaction of $595,000.00. Following the transaction, the chief financial officer now directly owns 9,811 shares of the company's stock, valued at approximately $1,167,509. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Mark C. Mckenna sold 25,000 shares of the business's stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $118.99, for a total transaction of $2,974,750.00. Following the completion of the sale, the chief executive officer now owns 55,144 shares in the company, valued at $6,561,584.56. The disclosure for this sale can be found here. Company insiders own 3.40% of the company's stock.
在其他新聞方面，首席執行官馬克·C·麥肯納在1月17日星期二的一次交易中出售了2.5萬股該公司的股票。這些股票以118.99美元的平均價格出售，總成交金額為2974,750.00美元。出售完成後，首席執行官現在擁有該公司55,144股，價值約6,561,584.56美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過這個環節。在其他新聞方面，首席財務官基思·W·馬歇爾在1月17日星期二的一次交易中出售了5,000股公司股票。這些股票以119.00美元的平均價格出售，總成交額為595,000.00美元。交易完成後，首席財務官現在直接持有該公司9811股股票，價值約1,167,509美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。此外，首席執行官馬克·C·麥肯納在1月17日星期二的交易中出售了25,000股該公司股票。股票以118.99美元的平均價格出售，總成交金額為2974,750.00美元。出售完成後，首席執行官現在擁有該公司55,144股，價值6,561,584.56美元。關於這次銷售的披露可以找到這裏。公司內部人士持有該公司3.40%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its position in Prometheus Biosciences by 2,632.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,366,426 shares of the biopharmaceutical company's stock worth $38,574,000 after purchasing an additional 1,316,426 shares in the last quarter. State Street Corp lifted its stake in Prometheus Biosciences by 226.9% in the third quarter. State Street Corp now owns 1,586,074 shares of the biopharmaceutical company's stock valued at $93,594,000 after buying an additional 1,100,857 shares during the last quarter. Fred Alger Management LLC lifted its stake in Prometheus Biosciences by 325.5% in the third quarter. Fred Alger Management LLC now owns 1,036,165 shares of the biopharmaceutical company's stock valued at $61,144,000 after buying an additional 792,620 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Prometheus Biosciences by 164.7% during the second quarter. Woodline Partners LP now owns 1,191,661 shares of the biopharmaceutical company's stock valued at $33,641,000 after purchasing an additional 741,403 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Prometheus Biosciences by 26.6% during the third quarter. Vanguard Group Inc. now owns 1,561,606 shares of the biopharmaceutical company's stock valued at $92,151,000 after purchasing an additional 328,397 shares during the period. 78.31% of the stock is currently owned by hedge funds and other institutional investors.
機構投資者和對衝基金最近增持或減持了該公司的股份。Point72 Asset Management L.P.在第二季度將其在普羅米修斯生物科學公司的頭寸增加了2632.9%。Point72 Asset Management L.P.在上個季度額外購買了1,316,426股後，現在擁有這家生物製藥公司1,366,426股股票，價值38,574,000美元。道富集團在第三季度增持了普羅米修斯生物科學公司的股份226.9%。道富集團目前持有這家生物製藥公司1,586,074股股票，價值93,594,000美元，此前該公司在上個季度又購買了1,100,857股。弗雷德·阿爾傑管理公司在第三季度將其在普羅米修斯生物科學公司的持股比例提高了325.5%。弗雷德·阿爾傑管理有限責任公司現在擁有這家生物製藥公司1,036,165股股票，價值61,144,000美元，上個季度又購買了792,620股。Woodline Partners LP在第二季度增持了普羅米修斯生物科學公司的股票164.7%。Woodline Partners LP現在擁有這家生物製藥公司1,191,661股股票，價值33,641,000美元，在此期間又購買了741,403股。最後，先鋒集團在第三季度增持了26.6%的普羅米修斯生物科學公司的股票。先鋒集團現在持有這家生物製藥公司1,561,606股股票，價值92,151,000美元，在此期間又購買了328,397股。78.31%的股票目前由對衝基金和其他機構投資者持有。
About Prometheus Biosciences
關於普羅米修斯生物科學公司
(Get Rating)
(獲取評級)
Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.
普羅米修斯生物科學公司是一家生物製藥公司，致力於治療炎症性腸病(IBD)的新型療法和伴隨診斷產品的發現、開發和商業化。它的主要產品包括PRA023，一種人源化的IgG1單抗(MAb)，正處於IIa期臨牀試驗，用於治療潰瘍性結腸炎和克羅恩病，以及系統性硬化症相關的間質性肺疾病。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Prometheus Biosciences (RXDX)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 免費獲取StockNews.com關於普羅米修斯生物科學的研究報告(RXDX)
- Bed Bath&Beyond正在繞着排水溝走
- Allegro MicroSystems是一隻定位良好的半導體股票
- 斯科特奇蹟-Gro觸底，比賽逆轉
- 奧馳亞是一隻大衰退的股票，長期前景不確定
- Novavax的股價在1月份大幅上漲，而其他股票則出現下滑
Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普羅米修斯生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對普羅米修斯生物科學公司和相關公司的最新新聞和分析師評級的每日簡要摘要。